Abstract
Neurodegenerative disorders are one of the most critical public health concerns of our times. Regrettably, therapeutic interventions currently available have shown only partial benefits to patients affected by one of these disorders. Although the important advances made during the last decades, several questions regarding physiopathological aspects of these diseases are still open. On this regard, the role of neuroinflammation is recognized as critical during the establishment and progression of the neurodegenerative process, and several authors have suggested that neuroinflammatory modulation should be at the basis of therapeutic treatment. In the present review we summarize the general aspects of the neuroinflammatory process and the cellular component of such response whose have been commonly related with the main neurodegenerative disorders, particularly Alzheimer’s and Parkinson’s disease, as well as, the main molecular events that might trigger the inflammatory process and affect neuronal support structures, such as the blood brain barrier, leading to neurodegeneration. Additionally, we discuss recent advances regarding Nuclear Receptors research, such as peroxisome proliferators-activated receptors and liver X receptor, and the molecular basis of its potential role against neuroinflammation and neurodegeneration.
Keywords: Neurodegeneration, chronic inflammation, inflammatory mediators, glial activation, nuclear receptors.
Current Pharmaceutical Design
Title:Recent Advances in Neuroinflammation Therapeutics: PPARs/LXR as Neuroinflammatory Modulators
Volume: 22 Issue: 10
Author(s): Sussy Bastias-Candia, Nicolas Garrido A., Juan M. Zolezzi and Nibaldo C. Inestrosa
Affiliation:
Keywords: Neurodegeneration, chronic inflammation, inflammatory mediators, glial activation, nuclear receptors.
Abstract: Neurodegenerative disorders are one of the most critical public health concerns of our times. Regrettably, therapeutic interventions currently available have shown only partial benefits to patients affected by one of these disorders. Although the important advances made during the last decades, several questions regarding physiopathological aspects of these diseases are still open. On this regard, the role of neuroinflammation is recognized as critical during the establishment and progression of the neurodegenerative process, and several authors have suggested that neuroinflammatory modulation should be at the basis of therapeutic treatment. In the present review we summarize the general aspects of the neuroinflammatory process and the cellular component of such response whose have been commonly related with the main neurodegenerative disorders, particularly Alzheimer’s and Parkinson’s disease, as well as, the main molecular events that might trigger the inflammatory process and affect neuronal support structures, such as the blood brain barrier, leading to neurodegeneration. Additionally, we discuss recent advances regarding Nuclear Receptors research, such as peroxisome proliferators-activated receptors and liver X receptor, and the molecular basis of its potential role against neuroinflammation and neurodegeneration.
Export Options
About this article
Cite this article as:
Bastias-Candia Sussy, Garrido A. Nicolas, Zolezzi M. Juan and Inestrosa C. Nibaldo, Recent Advances in Neuroinflammation Therapeutics: PPARs/LXR as Neuroinflammatory Modulators, Current Pharmaceutical Design 2016; 22 (10) . https://dx.doi.org/10.2174/1381612822666151223103038
DOI https://dx.doi.org/10.2174/1381612822666151223103038 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Prospective Role of Polyphenolic Compounds in the Treatment of Neurodegenerative Diseases
CNS & Neurological Disorders - Drug Targets Cortical Consequences of HIV-1 Tat Exposure in Rats are Enhanced by Chronic Cocaine
Current HIV Research New Insights into the Chemistry and Antioxidant Activity of Coumarins
Current Topics in Medicinal Chemistry Obesity and Metabolic Syndrome Affect the Cholinergic Transmission a nd Cognitive Functions
CNS & Neurological Disorders - Drug Targets Palmitoylethanolamide Regulates Production of Pro-Angiogenic Mediators in a Model of β Amyloid-Induced Astrogliosis <i>In Vitro</i>
CNS & Neurological Disorders - Drug Targets Recombinant Human Insulin-Like Growth Factor-1: A New Cardiovascular Disease Treatment Option?
Cardiovascular & Hematological Agents in Medicinal Chemistry A Role of the Parasympathetic Nervous System in Cognitive Training
Current Alzheimer Research Nicotinamide Phosphoribosyltransferase (Nampt): A Link Between NAD Biology, Metabolism, and Diseases
Current Pharmaceutical Design Hypoglycemia Induces Tau Hyperphosphorylation
Current Alzheimer Research Elicitation of Immune Responsiveness Against Antigenic Challenge in Age- Related Diseases: Effects of Red Wine Polyphenols
Current Pharmaceutical Design Chelating Agents for Neurodegenerative Diseases
Current Medicinal Chemistry Therapeutic Nucleic Acids
Recent Patents on Regenerative Medicine Modulation of Amyloid β Peptide1-42 Cytotoxicity and Aggregation in Vitro by Glucose and Chondroitin Sulfate
Current Alzheimer Research The Ambivalence of Early Diagnosis – Returning Results in Current Alzheimer Research
Current Alzheimer Research Non-Lipid Effects of Statins: Emerging New Indications
Current Vascular Pharmacology Meet Our Editorial Board Member
CNS & Neurological Disorders - Drug Targets The Role of Tau Phosphorylation in the Pathogenesis of Alzheimers Disease
Current Alzheimer Research Drug Trials in Dementia: Challenging Ethical Dilemmas
Current Alzheimer Research Therapeutic Effects of Herbal Chemicals in Traditional Chinese Medicine on Alzheimer’s Disease
Current Medicinal Chemistry Kinematic and Pressure Features of Handwriting and Drawing: Preliminary Results Between Patients with Mild Cognitive Impairment, Alzheimer Disease and Healthy Controls
Current Alzheimer Research